Vertex Receives the US FDA Approval for Journavx (Suzetrigine) to Treat Acute Pain

Shots:

• The FDA has approved Journavx (50mg; BID) to treat moderate-to-severe acute pain in adults
• JOURNAVX is an oral, non-opioid pain signal inhibitor that selectively targets NaV1.8 relative to other NaV channels
• The company is also testing suzetrigine for peripheral neuropathic pain (PNP), with ongoing P-III trial for diabetic neuropathy and plans for lumbosacral radiculopathy studies, subject to regulatory discussions

Ref: Vertex | Image: Vertex

Related News:- Orna Collaborates with Vertex to Develop Gene Therapies for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com